{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:22:47Z","timestamp":1772223767025,"version":"3.50.1"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Cutaneous drug hypersensitivity reactions (CDHRs) are a complicated area with multiple clinical manifestations and differential diagnoses, requiring differentiated diagnostic measurements and optimized therapeutic management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Disseminated CDHRs to classical drugs can be classified by a simple algorithm, whereas chemotherapeuticals or biopharmaceuticals may show drug-specific and atypical clinical presentations. Controversies in drug hypersensitivity diagnosis exist about the benefit and accuracy of in-vitro tests. Although skin tests are the best means of detecting sensitization to drugs, methods have not been sufficiently standardized. The necessity for skin tests before performing drug provocation test (DPT) and of prolonged DPTs is discussed in selected patients. If a suspicion has been documented, \u03b2-lactam allergy should be excluded. The standard allergy diagnosis is done by an allergist. In case of urgent need because of an infection and low risk according to history, faster delabeling pathways have been developed. There is weak evidence that patients with mastocytosis may have a slightly increased risk of developing immediate-type drug hypersensitivity; however, if considerations are taken, drugs do not have to be withheld for this patient group. There is particular need for improved diagnostic measurements in patients with drug-induced severe cutaneous adverse reactions (SCARs), both identifying the offending drug and detecting individuals at risk. Further challenges encompass appropriate treatments during the acute as well as chronic phase of SCARs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Recent literature has contributed to our understanding of clinical manifestations and existing controversies and future needs in this area.<\/jats:p><\/jats:sec>","DOI":"10.1097\/aci.0000000000000548","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:16:03Z","timestamp":1558754163000},"page":"308-318","source":"Crossref","is-referenced-by-count":6,"title":["Cutaneous drug hypersensitivity: developments and controversies"],"prefix":"10.1097","volume":"19","author":[{"given":"Knut","family":"Brockow","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology Biederstein, School of Medicine, Technical University of Munich, Munich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Pf\u00fctzner","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Medical Center, Gie\u00dfen and Marburg GmbH, Philipps Universit\u00e4t, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"R3-20230828","doi-asserted-by":"crossref","DOI":"10.5070\/D32311037249","article-title":"Pityriasis lichenoides-like drug reaction: a clinical histopathologic study of 10 cases","volume":"23","author":"Magro","year":"2017","journal-title":"Dermatol Online J"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ced.13751","article-title":"Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma","volume":"44","author":"Chen","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s12094-018-1891-7","article-title":"Cutaneous toxicities of new treatments for melanoma","volume":"20","author":"Boada","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","article-title":"Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy","volume":"79","author":"Rzepecki","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40413-018-0224-1","article-title":"Important questions in drug allergy and hypersensitivity: consensus papers from the 2018\u200aAAAAI\/WAO international drug allergy symposium","volume":"11","author":"Demoly","year":"2018","journal-title":"World Allergy Organ J"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: in vitro testing","volume":"143","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaip.2018.07.037","article-title":"Controversies in drug allergy: drug allergy pathways","volume":"7","author":"Chiriac","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2018.07.051","article-title":"Controversies in drug allergy: beta-lactam hypersensitivity testing","volume":"7","author":"Torres","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaip.2018.06.030","article-title":"Controversies in drug allergy: radiographic contrast media","volume":"7","author":"Sanchez-Borges","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.anai.2010.06.014","article-title":"Use of commercial antipenicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy","volume":"105","author":"Macy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2017.08.009","article-title":"Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy","volume":"6","author":"Salas","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2016.11.006","article-title":"Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/all.12886","article-title":"In vitro tests for drug hypersensitivity reactions: an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"71","author":"Mayorga","year":"2016","journal-title":"Allergy"},{"key":"R22-20230828","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.15509","article-title":"Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions","author":"Samuelov","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaad.2018.10.039","article-title":"Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions","volume":"80","author":"Mori","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.0105-4538.2001.00001.x-i8","article-title":"General considerations for skin test procedures in the diagnosis of drug hypersensitivity","volume":"57","author":"Brockow","year":"2002","journal-title":"Allergy"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs: an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaip.2018.09.008","article-title":"Controversies in allergy: is skin testing required prior to drug challenges?","volume":"7","author":"Macy","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"e160033","DOI":"10.1001\/jamapediatrics.2016.0033","article-title":"Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children","volume":"170","author":"Mill","year":"2016","journal-title":"JAMA Pediatr"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaip.2018.05.008","article-title":"Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing","volume":"7","author":"Iammatteo","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R29-20230828","first-page":"547","article-title":"Contrast media and dyes hypersensitivity","volume":"14","author":"Brockow","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1398-9995.2008.01832.x","article-title":"Skin testing in patients with hypersensitivity reactions to iodinated contrast media: a European multicenter study","volume":"64","author":"Brockow","year":"2009","journal-title":"Allergy"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2222.2010.03493.x","article-title":"Clinical value of negative skin tests to iodinated contrast media","volume":"40","author":"Caimmi","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/all.13603","article-title":"Tolerability of iobitridol in patients with nonimmediate hypersensitivity reactions to iodinated contrast media","volume":"74","author":"Gracia-Bara","year":"2019","journal-title":"Allergy"},{"key":"R33-20230828","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17835","article-title":"Are drug intradermal tests dangerous to explore cross-reactivity and co-sensitization in DRESS?","author":"Soria","year":"2019","journal-title":"Br J Dermatol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/pai.12826","article-title":"Nonimmediate-reading skin tests and prolonged challenges in nonimmediate hypersensitivity to beta-lactams in children","volume":"29","author":"Lezmi","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaip.2018.06.023","article-title":"Provocation tests in nonimmediate hypersensitivity reactions to beta-lactam antibiotics in children: are extended challenges needed?","volume":"7","author":"Garcia Rodriguez","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jaip.2017.10.008","article-title":"Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test","volume":"6","author":"Tonson la Tour","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R38-20230828","doi-asserted-by":"crossref","DOI":"10.1111\/all.13721","article-title":"A EAACI drug allergy interest group survey on how European allergy specialists deal with beta-lactam allergy","author":"Torres","year":"2019","journal-title":"Allergy"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.anai.2016.04.021","article-title":"Penicillin skin testing in hospitalized patients with beta-lactam allergies: effect on antibiotic selection and cost","volume":"117","author":"King","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaip.2018.08.009","article-title":"Triage strategies for clarifying reported betalactam allergy","volume":"7","author":"Brockow","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jaip.2016.03.009","article-title":"The high impact of penicillin allergy registration in hospitalized patients","volume":"4","author":"van Dijk","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s40629-015-0052-6","article-title":"Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (OGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)","volume":"24","author":"Brockow","year":"2015","journal-title":"Allergo J Int"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jaci.2017.02.005","article-title":"Tackling inpatient penicillin allergies: assessing tools for antimicrobial stewardship","volume":"140","author":"Blumenthal","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/all.12774","article-title":"Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group","volume":"71","author":"Gomes","year":"2016","journal-title":"Allergy"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity: a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaip.2017.03.032","article-title":"Treating through\u2019 decision and follow-up in antibiotic therapy-associated exanthemas","volume":"5","author":"Trautmann","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaip.2018.04.042","article-title":"Long-term follow-up after penicillin allergy delabeling in ambulatory patients","volume":"7","author":"Lachover-Roth","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/all.12929","article-title":"Drug allergy passport and other documentation for patients with drug hypersensitivity: an ENDA\/EAACI Drug Allergy Interest Group Position Paper","volume":"71","author":"Brockow","year":"2016","journal-title":"Allergy"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jaip.2018.01.020","article-title":"Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins","volume":"6","author":"Romano","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jaip.2018.01.033","article-title":"Allergic myocardial infarction (Kounis syndrome) after cefuroxime with side-chain cross-reactivity","volume":"6","author":"Absmaier","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/all.13168","article-title":"Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis","volume":"72","author":"Sacco","year":"2017","journal-title":"Allergy"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaip.2018.05.025","article-title":"A retrospective critical analysis and risk stratification of penicillin allergy de-labelling in a UK Specialist Regional Allergy Service","volume":"7","author":"Mohamed","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jaip.2018.07.048","article-title":"Pathways to improved antibiotic allergy and antimicrobial stweardship practice: the validation of a beta-lactam antibiotic allergy assessment tool","volume":"7","author":"Devchand","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/all.13037","article-title":"Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity","volume":"72","author":"Chiriac","year":"2017","journal-title":"Allergy"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e328355b7cb","article-title":"Drug allergy in mast cell disease","volume":"12","author":"Brockow","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/cea.12882","article-title":"Vaccination management in children and adults with mastocytosis","volume":"47","author":"Zanoni","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/all.13445","article-title":"Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: the results of a double-blind, placebo-controlled challenge study","volume":"73","author":"Hermans","year":"2018","journal-title":"Allergy"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.2174\/1381612822666160928125152","article-title":"Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options","volume":"22","author":"Paulmann","year":"2016","journal-title":"Curr Pharm Des"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Derm"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fped.2018.00026","article-title":"Vancomycin-induced Stevens-Johnson-Syndrome in a boy under 2 years old: an early diagnosis by granulysin rapid test","volume":"6","author":"Lin","year":"2018","journal-title":"Front Ped"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","article-title":"Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Fujita","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The function of HLA-B\u221713:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ijd.14174","article-title":"Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement","volume":"57","author":"Intarasupht","year":"2018","journal-title":"Int J Dermatol"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jbcr\/irx016","article-title":"How does SCORTEN score?","volume":"39","author":"Zavala","year":"2018","journal-title":"J Burn Care Res"},{"key":"R69-20230828","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jid.2017.01.003","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done","volume":"137","author":"Stern","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: a key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s40629-014-0020-6","article-title":"Cellular in vitro diagnosis of adverse drug reactions","volume":"23","author":"M\u00f6bs","year":"2014","journal-title":"Allergo J Int"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jid.2016.04.009","article-title":"Research techniques made simple: monitoring of T-cell subsets using the ELISPOT assay","volume":"136","author":"M\u00f6bs","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/jdv.14890","article-title":"The measurement of drug-induced interferon \u03b3-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions","volume":"32","author":"Suthumchai","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2017.09.004","article-title":"The combined utility of ex vivo IFN-\u03b3 release Enzyme-Linked ImmunoSpot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions","volume":"6","author":"Trubiano","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R77-20230828","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"Human leukocyte antigens: key regulators of T-cell mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.humimm.2016.01.020","article-title":"The IPD-IMGT\/HLA database: new developments in reporting HLA variation","volume":"77","author":"Robinson","year":"2016","journal-title":"Hum Immunol"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The function of HLA-B\u221713:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R81-20230828","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3904\/kjim.2018.126","article-title":"Genetic markers of cutaneous adverse reactions","volume":"33","author":"Jung","year":"2018","journal-title":"Korean J Intern Med"},{"key":"R82-20230828","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/epi.14599","article-title":"Temporal trends and patterns in carbamazepine use, related severe cutaneous adverse reactions, and HLA-B\u221715:02 screening: a nationwide study","volume":"59","author":"Lin","year":"2018","journal-title":"Epilepsia"},{"key":"R83-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0000000000000359","article-title":"Utility of human leukocyte antigen-B\u221758: 01 genotyping and patient outcomes","volume":"29","author":"Ke","year":"2019","journal-title":"Pharmacogenet Genomics"},{"key":"R84-20230828","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaip.2018.11.039","article-title":"The Presence of HLA-B75, DR13 homozygosity, or DR14 additionally increases the risk of allopurinol-induced severe cutaneous adverse reactions in HLA-B\u221758:01 carriers","volume":"7","author":"Shim","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4168\/aair.2018.10.5.555","article-title":"The Fas signaling pathway is a common genetic risk factor for severe cutaneous drug adverse reactions across diverse drugs","volume":"10","author":"Park","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"R86-20230828","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjo.2007.136796","article-title":"Association of Fas ligand gene polymorphism with Stevens-Johnson syndrome","volume":"92","author":"Ueta","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R87-20230828","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R88-20230828","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R89-20230828","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jid.2017.07.828","article-title":"New evidence supporting cyclosporine efficacy in epidermal necrolysis","volume":"137","author":"Roujeau","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R90-20230828","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Infl Res"},{"key":"R91-20230828","doi-asserted-by":"crossref","first-page":"e12758","DOI":"10.1111\/dth.12758","article-title":"Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"32","author":"Gilbert","year":"2019","journal-title":"Dermatol Ther"},{"key":"R92-20230828","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R93-20230828","first-page":"1","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R94-20230828","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF- \u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"R95-20230828","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40264-017-0608-0","article-title":"Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"41","author":"Olteanu","year":"2018","journal-title":"Drug Saf"},{"key":"R96-20230828","first-page":"2027","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: a case report and literature review","volume":"16","author":"Xu","year":"2018","journal-title":"Exp Ther Med"},{"key":"R97-20230828","first-page":"S5","article-title":"Bronchiolitis obliterans and severe ocular disease as long-term sequelae of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series of 3 children","volume":"35","author":"Seccombe","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"R98-20230828","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bjd.17267","article-title":"Posttraumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients","volume":"180","author":"Hefez","year":"2019","journal-title":"Br J Dermatol"},{"key":"R99-20230828","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130832-201908000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:54:33Z","timestamp":1721321673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201908000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000548","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}